Vitamin E and Alzheimer disease: The basis for additional clinical trials

American Journal of Clinical Nutrition

Volumn 71, Issue 2, 2000, Pages

  Grundman, Michael ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Alzheimers Disease Cooperative Study (ADCS)   (United States)

Author keywords

Alzheimer disease; Alzheimer's Disease Cooperative Study; Clinical trials; Elderly; Free radicals; Mild cognitive impairment; Oxidative stress; Vitamin E; amyloid

Indexed keywords

ALPHA TOCOPHEROL; AMYLOID BETA PROTEIN; FREE RADICAL;

ALZHEIMER DISEASE; BRAIN INJURY; COGNITIVE DEFECT; CONFERENCE PAPER; ELDERLY CARE; HUMAN; MEDICAL RESEARCH; OXIDATIVE STRESS; PRACTICE GUIDELINE;

ANIMALIA;

EID: 0033958696     PISSN: 00029165     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajcn/71.2.630s     Document Type: Conference Paper

References (94)

1. Katzman R, Kawas C. The epidemiology of dementia and Alzheimer disease. In: Terry RD, Katzman R, Bick KL, eds. Alzheimer disease. New York: Raven Press, 1994:105-19.
2. Selkoe DJ. Cell biology of the beta-amyloid precursor protein and the genetics of Alzheimer's disease. Cold Spring Harb Symp Quant Biol 1996;61:587-96.
3. McGeer PL, McGeer EG. The inflammatory response system of brain: implications for therapy of Alzheimer and other neurodegenerative diseases. Brain Res Brain Res Rev 1995;21:195-218.
4. Beal MF. Mitochondria, free radicals, and neurodegeneration. Curr Opin Neurobiol 1996;6:661-6.
5. Terry RD. The pathogenesis of Alzheimer disease: an alternative to the amyloid hypothesis. J Neuropathol Exp Neurol 1996;55:1023-5.
6. Jackson GR, Werrbach-Perez K, Pan Z, Sampath D, Perez-Polo JR. Neurotrophin regulation of energy homeostasis in the central nervous system. Dev Neurosci 1994;16:285-90.
7. Halliwell B, Gutteridge J. Oxygen radicals and the nervous system. Trends Neurosci 1985;8:22-6.
8. Balazs L, Leon M. Evidence of an oxidative challenge in the Alzheimer's brain. Neurochem Res 1994;19:1131-7.
9. Palmer AM, Burns MA. Selective increase in lipid peroxidation in the inferior temporal cortex in Alzheimer's disease. Brain Res 1994;645:338-42.
10. Hensley K, Hall N, Subramaniam R, et al. Brain regional correspondence between Alzheimer's disease histopathology and biomarkers of protein oxidation. J Neurochem 1995;65:2146-56.
11. Mecocci P, MacGarvey U, Beal MF. Oxidative damage to mitochondrial DNA is increased in Alzheimer's disease. Ann Neurol 1994;36:747-51.
12. Premkumar DR, Smith MA, Richey PL, et al. Induction of heme oxygenase-1 mRNA and protein in neocortex and cerebral vessels in Alzheimer's disease. J Neurochem 1995;65:1399-402.
13. Good PF, Werner P, Hsu A, Olanow CW, Perl DP. Evidence of neuronal oxidative damage in Alzheimer's disease. Am J Pathol 1996;149:21-8.
14. Smith MA, Richey Harris PL, Sayre LM, Beckman JS, Perry G. Widespread peroxynitrite-mediated damage in Alzheimer's disease. J Neurosci 1997;17:2653-7.
15. van der Vliet A, Eiserich JP, Halliwell B. Cross CE. Formation of reactive nitrogen species during peroxidase-catalyzed oxidation of nitrite. A potential additional mechanism of nitric oxide-dependent toxicity. J Biol Chem 1997;272:7617-25.
16. Eiserich JP, Hristova M, Cross CE, et al. Formation of nitric oxide-derived inflammatory oxidants by myeloperoxidase in neutrophils. Nature 1998;391:393-7.
17. Nagra RM, Becher B, Tourtellotte WW, et al. Immunohistochemical and genetic evidence of myeloperoxidase involvement in multiple sclerosis. J Neuroimmunol 1997;78:97-107.
18. Schipper HM, Cisse S, Stopa EG. Expression of heme oxygenase-1 in the senescent and Alzheimer-diseased brain. Ann Neurol 1995;37: 758-68.
19. Smith MA, Kutty RK, Richey PL, et al. Heme oxygenase-1 is associated with the neurofibrillary pathology of Alzheimer's disease. Am J Pathol 1994;145:42-7.
20. Yan SD, Chen X, Schmidt AM, et al. Glycated tau protein in Alzheimer disease: a mechanism for induction of oxidant stress. Proc Natl Acad Sci U S A 1994;91:7787-91.
21. Smith MA, Perry G, Richey PL, et al. Oxidative damage in Alzheimer's. Nature 1996;382:120-1.
22. Furuta A, Price DL, Pardo CA, et al. Localization of superoxide dismutases in Alzheimer's disease and Down's syndrome neocortex and hippocampus. Am J Pathol 1995;146:357-67.
23. Pappolla MA, Omar RA, Kim KS, Rohakis NK. Immunohistochemical evidence of antioxidant stress in Alzheimer's disease. Am J Pathol 1992;140:621-8.
24. Pike CJ, Burdick D, Walencewicz AJ, Glabe CG, Cotman CW. Neurodegeneration induced by beta-amyloid peptides in vitro: the role of peptide assembly state. J Neurosci 1993;13:1676-87.
25. Simmons LK, May PC, Tomaselli KJ, et al. Secondary structure of amyloid beta peptide correlates with neurotoxic activity in vitro. Mol Pharmacol 1994;45:373-9.
26. Butterfield DA, Hensley K, Harris M, Mattson M, Carney J. β-Amyloid peptide free radical fragments initiate synaptosomal lipoperoxidatian in a sequence-specific fashion: implications to Alzheimer's disease. Biochem Biophys Res Commun 1994;200:710-5.
27. Hensley K, Carney JM, Mattson MP, et al. A model for beta-amyloid aggregation and neurotoxicity based on free radical generation by the peptide: relevance to Alzheimer disease. Proc Natl Acad Sci USA 1994;91:3270-4.
28. Behl C. Davis JB, Lesley R, Schubert D. Hydrogen peroxide mediates amyloid beta protein toxicity. Cell 1994;77:817-27.
29. Meda L, Cassatella MA, Szendrei GI, et al. Activation of microglial cells by beta-amyloid protein and interferon-gamma. Nature 1995;374:647-50.
30. Mutisya EM, Bowling AC, Beal MF. Cortical cytochrome oxidase activity is reduced in Alzheimer's disease. J Neurochem 1994; 63:2179-84.
31. Parker WD Jr, Parks J, Filley CM, Kleinschmidt-DeMasters BK. Electron transport chain defects in Alzheimer's disease brain. Neurology 1994;44:1090-6.
32. Beal MF, Hyman BT, Koroshetz W. Do defects in mitochondrial energy metabolism underlie the pathology of neurodegenerative diseases? Trends Neurosci 1993;16:125-31.
33. Parker WD Jr, Filley CM, Parks JK. Cytochrome oxidase deficiency in Alzheimer's disease. Neurology 1990;40:1302-3.
34. Davis RE, Miller S, Herrnstadt C, et al. Mutations in mitochondrial cytochrome c oxidase genes segregate with late-onset Alzheimer disease. Proc Natl Acad Sci USA 1997;94:4526-31.
35. Connor JR, Snyder BS, Beard JL, Fine RE, Mufson EJ. Regional distribution of iron and iron-regulatory proteins in the brain in aging and Alzheimer's disease. J Neurosci Res 1992;31:327-35.
36. Good PF, Perl DP, Bierer LM, Schmeidler J. Selective accumulation of aluminum and iron in the neurofibrillary tangles of Alzheimer's disease: a laser microprobe (LAMMA) study. Ann Neurol 1992;31:286-92.
37. Grundke-Iqbal I, Fleming J, Tung YC, Lassmann H, Iqbal K, Joshi JG. Ferritin is a component of the neuritic (senile) plaque in Alzheimer dementia. Acta Neuropathol (Berl) 1990;81:105-10.
38. Multhaup G, Schlicksupp A, Hesse L, et al. The amyloid precursor protein of Alzheimer's disease in the reduction of copper(II) to copper(I). Science 1996;271:1406-9.
39. Chen L, Richardson JS, Caldwell JE, Ang LC. Regional brain activity of free radical defense enzymes in autopsy samples from patients with Alzheimer's disease and from nondemented controls. Int J Neurosci 1994;75:83-90.
40. Adams JD Jr, Klaidman LK, Odunze IN, Shen HC, Miller CA. Alzheimer's and Parkinson's disease. Brain levels of glutathione, glutathione disulfide, and vitamin E. Mol Chem Neuropathol 1991;14:213-26.
41. Jeandel C, Nicolas MB, Dubois F, Nabel-Belleville F, Penin F, Cuny G. Lipid peroxidation and free radical scavengers in Aizheimer's disease. Gerontology 1989;35:275-82.
42. Perrin R, Briancon S, Jeandel C, et al. Blood activity of Cu/Zn superoxide dismutase, glutathione peroxidase and catalase in Aizheimer's disease: a case-control study. Gerontology 1990;36:306-13.
43. Metcalfe T, Bowen DM, Muller DP. Vitamin E concentrations in human brain of patients with Aizheimer's disease, fetuses with Down's syndrome, centenarians, and controls. Neurochem Res 1989;14:1209-12.
44. Jackson CV, Holland AJ, Williams CA, Dickerson JW. Vitamin E and Aizheimer's disease in subjects with Down's syndrome. J Ment Defic Res 1988;32:479-84.
45. Zaman Z, Roche S, Fielden P, Frost PG, Niriella DC, Cayley AC. Plasma concentrations of vitamins A and E and carotenoids in Aizheimer's disease. Age Ageing 1992;21:91-4.
46. Meydani M. Vitamin E. Lancet 1995;345:170-5.
47. Goodman Y, Mattson MP. Secreted forms of beta-amyloid precursor protein protect hippocampal neurons against amyloid beta-peptide-induced oxidative injury. Exp Neurol 1994;128:1-12.
48. Behl C, Davis J, Cole GM, Schubert D. Vitamin E protects nerve cells from amyloid beta protein toxicity. Biochem Biophys Res Commun 1992;186:944-50.
49. Murphy TH, Schnaar RL, Coyle JT. Immature cortical neurons are uniquely sensitive to glutamate toxicity by inhibition of cystine uptake. FASEB J 1990;4:1624-33.
50. Trojanowski JQ, Lee VM. Phosphorylation of paired helical filament tau in Aizheimer's disease neurofibrillary lesions: focusing on phosphatases. FASEB J 1995;9:1570-6.
51. Ledesma MD, Bonay P, Colaco C, Avila J. Analysis of microtubuleassociated protein tau glycation in paired helical filaments. J Biol Chem 1994;269:21614-9.
52. Smith MA, Sayre LM, Monnier VM, Perry G. Radical AGEing in Aizheimer's disease. Trends Neurosci 1995;18:172-6.
53. Schweers O, Mandelkow EM, Biernat J, Mandelkow E. Oxidation of cysteine-322 in the repeat domain of microtubule-associated protein tau controls the in vitro assembly of paired helical filaments. Proc Natl Acad Sci U S A 1995;92:8463-7.
54. Pillai SR, Traber MG, Steiss JE, Kayden HJ, Cox NR. Alpha-tocopherol concentrations of the nervous system and selected tissues of adult dogs fed three levels of vitamin E. Lipids 1993;28:1101-5.
55. Monji A, Morimoto N, Okuyama I, Yamashita N, Tashiro N. Effect of dietary vitamin E on lipofuscin accumulation with age in the rat brain. Brain Res 1994;634:62-8.
56. Meydani M, Macauley JB, Blumberg JB. Effect of dietary vitamin E and selenium on susceptibility of brain regions to lipid peroxidation. Lipids 1988;23:405-9.
57. Vatassery GT, Brin MF, Farm S, Kayden HJ, Traber MG. Effect of high doses of dietary vitamin E on the concentrations of vitamin E in several brain regions, plasma, liver, and adipose tissue of rats. J Neurochem 1988;51:621-3.
58. Carney JM, Starke-Reed PE, Oliver CN, et al. Reversal of age-related increase in brain protein oxidation, decrease in enzyme activity, and loss in temporal and spatial memory by chronic administration of the spin-trapping compound N-tert-butyl-alpha-phenyl-nitrone. Proc Natl Acad Sci USA 1991;88:3633-6.
59. Socci DJ, Crandall BM, Arendash GW. Chronic antioxidant treatment improves the cognitive performance of aged rats. Brain Res 1995;693:88-94.
60. Ichitani Y, Okaichi H, Yoshikawa T, Ibata Y. Learning behaviour in chronic vitamin E-deficient and -supplemented rats: radial arm maze learning and passive avoidance response. Behav Brain Res 1992;51:157-64.
61. Wortwein G, Stackman RW, Walsh TJ. Vitamin E prevents the place learning deficit and the cholinergic hypofunction induced by AF64A. Exp Neurol 1994;125:15-21.
62. Hara H, Kato H, Kogure K. Protective effect of alpha-tocopherol on ischemic neuronal damage in the gerbil hippocampus. Brain Res 1990;510:335-8.
63. Hsiao KK, Borchelt DR, Olson K, et al. Age-related CNS disorder and early death in transgenic FVB/N mice overexpressing Alzheimer amyloid precursor proteins. Neuron 1995; 15:1203-18.
64. Sano M, Ernesto C, Thomas RG, et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. N Engl J Med 1997;336:1216-22.
65. Jenner P, Olanow CW. Oxidative stress and the pathogenesis of Parkinson's disease. Neurology 1996;47:S161-70.
66. Blessed G, Tomlinson BE, Roth M. The association between quantitative measures of dementia and senile change in the grey matter of elderly subjects. Br J Psychiatry 1968;114:797-811.
67. Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 1993;43:2412-4.
68. The Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 1993;328:176-83.
69. Kitagawa M, Mino M. Effects of elevated d-alpha(RRR)-tocopherol dosage in man. J Nutr Sci Vitaminol (Tokyo) 1989;35:133-42.
70. Bierenbaum M, Noonan F, Machlin L, et al. The effect of supplemental vitamin E on serum parameters in diabetic, post coronary and normal subjects. Nutr Rep Int 1985;31:1171-80.
71. Stampfer MJ, Willett W, Castelli WP, Taylor JO, Fine J, Hennekens CH. Effect of vitamin E on lipids. Am J Clin Pathol 1983;79:714-6.
72. Tsai AC, Kelley JJ, Peng B, Cook N. Study on the effect of mega-vitamin E supplementation in man. Am J Clin Nutr 1978;31:831-7.
73. Gillilan RE, Mondell B, Warbasse JR. Quantitative evaluation of vitamin E in the treatment of angina pectoris. Am Heart J 1977;93: 444-9.
74. Pappert EJ, Tangney CC, Goetz CG, et al. Alpha-tocopherol in the ventricular cerebrospinal fluid of Parkinson's disease patients: dose-response study and correlations with plasma levels. Neurology 1996;47:1037-42.
75. Fahn S. A pilot trial of high-dose alpha-tocopherol and ascorbate in early Parkinson's disease. Ann Neurol 1992;32(suppl):S128-32.
76. Brin M, Fahn S, Loftus S, McMahan D, Flaster E. Relationship between dose of vitamin E administered and blood levels. Ann N Y Acad Sci 1989;570:421-4.
77. Anderson TW, Reid DB. A double-blind trial of vitamin E in angina pectoris. Am J Clin Nutr 1974;27:1174-8.
78. Smith GE, Petersen RC, Parisi JE, Ivnik RJ. Definition, course, and outcome of mild cognitive impairment. Aging Neuropsychol Cogn 1996;3:141-7.
79. McBee WL, Dailey ME, Dugan E, Shumaker SA. Hormone replacement therapy and other potential treatments for dementias. Endocrinol Metab Clin North Am 1997;26:329-45.
80. Rubin EH, Morris JC, Grant EA, Vendegna T. Very mild senile dementia of the Alzheimer type. I. Clinical assessment. Arch Neurol 1989;46:379-82.
81. Flicker C, Ferris SH, Reisberg B. Mild cognitive impairment in the elderly: predictors of dementia. Neurology 1991;41:1006-9.
82. Reisberg B, Ferris SH, de Leon MJ, Crook T. The Global Deterioration Scale for assessment of primary degenerative dementia. Am J Psychiatry 1982;139:1136-9.
83. Bowen J, Teri L, Kukull W, McCormick W, McCurry SM, Larson EB. Progression to dementia in patients with isolated memory loss. Lancet 1997;349:763-5.
84. Petersen RC, Smith GE, Ivnik RJ, et al. Apolipoprotein E status as a predictor of the development of Alzheimer's disease in memory-impaired individuals. JAMA 1995;273:1274-8.
85. Grundman M, Petersen RC, Morris JC. et al. Rate of dementia of Alzheimer type (DAT) in subjects with mild cognitive impairment. The ADCS Cooperative Study. Neurology 1996;46:A403 (abstr).
86. Masur DM, Sliwinski M, Lipton RB, Blau AD, Crystal HA. Neuropsychological prediction of dementia and the absence of dementia in healthy elderly persons. Neurology 1994;44:1427-32.
87. Tierney MC, Szalai JP, Snow WG, et al. Prediction of probable Alzheimer's disease in memory-impaired patients: a prospective longitudinal study. Neurology 1996;46:661-5.
88. Poirier J, Delisle MC, Quirion R, et al. Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer disease. Proc Natl Acad Sci U S A 1995;92:12260-4.
89. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-44.
90. Farrer LA, Cupples LA, Blackburn S, et al. Interrater agreement for diagnosis of Alzheimer's disease: the MIRAGE Study. Neurology 1994;44:652-6.
91. Blacker D, Albert MS, Bassett SS, Go RC, Harrell LE, Folstein MF. Reliability and validity of NINCDS-ADRDA criteria for Alzheimer's disease. The National Institute of Mental Health Genetics Initiative. Arch Neurol 1994;51:1198-204.
92. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state." A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-98.
93. Galasko D, Bennett D, Sano M, et al. An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord 1997;11(suppl):S33-9.
94. Wechsler D. WMS-R Wechsler Memory Scale. Revised manual. New York: The Psychological Corporation, Harcourt Brace Jovanovich, 1987.